Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 5Neoplasm Metastasis 3Neuroectodermal Tumors, Primitive 2Neoplasms 2Uterine Neoplasms 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Perivascular Epithelioid Cell Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Hamartoma Syndrome, Multiple 1Endometrial Neoplasms 1Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Breast Diseases 1Angiomyolipoma 1Advanced Solid Tumor 1

Interventions

dactolisib 2Everolimus 2surufatinib 1spartalizumab 1pasireotide 1ganitumab 1fosbretabulin 1cixutumumab 1TH 302 1PM 00104 1ONC206 1Fentanyl 1CLR1404 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neuroectodermal Tumors, Primitive × dactolisib × Clear all
NCT01658436 2016-05-02

BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.

Novartis

Phase 2 Completed
31 enrolled 7 charts

Neuroectodermal Tumors, Primitive

NCT01628913 2016-04-07

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Novartis

Phase 2 Terminated
62 enrolled 7 charts
EndocrineNET

Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡